Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.”In the company’s words, NCT07365332 on ClinicalTrials.gov
Other drugs for Pulmonary Arterial Hypertension
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- MacitentanActelion · Phase 3
- Macitentan/Tadalafil FDCActelion · Phase 3
- SelexipagActelion · Phase 3
Coming up2
- Jun 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2029 | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) | |
| Phase 3Not yet recruiting | 30 Jun 2030 | Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026